In 81 adults with treatment-resistant depression, a single day of inhaled GH001 (mebufotenin) lowered MADRS scores at day 8 more than placebo (LS mean difference −15.5). Secondary remission was 57.5% vs 0%; no severe or serious adverse events occurred.
RCTn = 81
Cubala et al. GH001 vs Placebo in Patients With Treatment-Resistant Depression: A Randomized Clinical Trial